Quest Diagnostics Incorporated (NYSE:DGX) Receives $236.31 Average PT from Analysts

Posted by George Bondi on Sep 20th, 2026

Shares of Quest Diagnostics Incorporated (NYSE:DGX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the thirteen brokerages that are currently covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $236.3077.

Several equities research analysts have commented on DGX shares. Barclays boosted their target price on Quest Diagnostics from $230.00 to $250.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Robert W. Baird lifted their price objective on shares of Quest Diagnostics from $236.00 to $255.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Mizuho boosted their price objective on shares of Quest Diagnostics from $235.00 to $260.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Truist Financial boosted their price objective on shares of Quest Diagnostics from $225.00 to $250.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Finally, JPMorgan Chase & Co. increased their target price on shares of Quest Diagnostics from $220.00 to $250.00 and gave the stock a “neutral” rating in a report on Tuesday, July 28th.

View Our Latest Research Report on Quest Diagnostics

Insider Transactions at Quest Diagnostics

In other news, SVP Mark Delaney sold 1,600 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total value of $376,288.00. Following the completion of the transaction, the senior vice president owned 10,335 shares in the company, valued at $2,430,585.30. This trade represents a 13.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Michael Prevoznik sold 22,677 shares of Quest Diagnostics stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $243.11, for a total value of $5,513,005.47. Following the completion of the sale, the senior vice president directly owned 37,557 shares in the company, valued at approximately $9,130,482.27. This represents a 37.65% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 34,277 shares of company stock worth $8,316,493 in the last three months. Insiders own 0.88% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Concurrent Investment Advisors LLC lifted its stake in Quest Diagnostics by 1.2% in the second quarter. Concurrent Investment Advisors LLC now owns 5,183 shares of the medical research company’s stock valued at $1,099,000 after acquiring an additional 62 shares during the last quarter. PFG Private Wealth Management LLC increased its stake in shares of Quest Diagnostics by 5.1% during the 2nd quarter. PFG Private Wealth Management LLC now owns 1,453 shares of the medical research company’s stock worth $308,000 after purchasing an additional 71 shares during the last quarter. Hantz Financial Services Inc. increased its stake in shares of Quest Diagnostics by 9.6% during the 4th quarter. Hantz Financial Services Inc. now owns 835 shares of the medical research company’s stock worth $145,000 after purchasing an additional 73 shares during the last quarter. Koshinski Asset Management Inc. raised its holdings in shares of Quest Diagnostics by 4.2% in the 1st quarter. Koshinski Asset Management Inc. now owns 2,062 shares of the medical research company’s stock valued at $404,000 after purchasing an additional 84 shares during the period. Finally, Wedmont Private Capital raised its holdings in shares of Quest Diagnostics by 2.8% in the 2nd quarter. Wedmont Private Capital now owns 3,120 shares of the medical research company’s stock valued at $647,000 after purchasing an additional 86 shares during the period. Institutional investors and hedge funds own 88.06% of the company’s stock.

Quest Diagnostics Price Performance

Shares of NYSE DGX opened at $246.65 on Tuesday. The company has a fifty day moving average price of $233.26 and a 200 day moving average price of $210.64. The firm has a market cap of $27.22 billion, a PE ratio of 26.18, a PEG ratio of 2.25 and a beta of 0.55. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.72. Quest Diagnostics has a 1-year low of $171.18 and a 1-year high of $248.70.

Quest Diagnostics (NYSE:DGX – Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, topping the consensus estimate of $2.82 by $0.30. The company had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.Quest Diagnostics’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.62 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Research analysts predict that Quest Diagnostics will post 11.15 earnings per share for the current fiscal year.

Quest Diagnostics Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 21st. Shareholders of record on Tuesday, October 6th will be given a dividend of $0.86 per share. The ex-dividend date of this dividend is Tuesday, October 6th. This represents a $3.44 annualized dividend and a yield of 1.4%. Quest Diagnostics’s payout ratio is 36.52%.

About Quest Diagnostics

(Get Free Report)

Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing used to help diagnose, monitor and manage diseases and other health conditions, serving physicians, hospitals, health plans, employers, government agencies and individual consumers.

Its services include routine blood and urine testing, advanced and esoteric diagnostics, molecular and genetic testing, anatomic pathology, cancer testing, drug screening and wellness-related assessments.